Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. First introduced in ...

Investing.com - European stocks traded in a lackluster fashion on Wednesday, as investors cautiously await the U.S. Federal Reserve’s interest rate decision later in the session. The DAX index... Oil ...